Compare GSK plc (GSK) vs Tapestry, Inc. (TPR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
GSK plc vs Tapestry, Inc. — how do they compare? GSK plc trades at $52.68 (market cap $101.34B), while Tapestry, Inc. trades at $144.07 (market cap $28.34B). The key difference: GSK plc is far larger — about 3.6× Tapestry, Inc.'s market cap, and GSK plc pays the higher dividend (3.49%). Which is the better fit depends on your goals.
| GSK | TPR | |
|---|---|---|
Market Cap | $101.34B | $28.34B |
Sector | Health | Consumer Cyclical |
52-Week High | $61.18 | $160.49 |
52-Week Low | $36.20 | $95.69 |
Enterprise Value | $121.95B | $31.19B |
Dividend Yield | 3.49% | 1.14% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GSK trades at $52.64, up 2.7% on the day, with a bearish technical signal despite recent earnings beats. The company reported Q1 2026 EPS of $1.24, beating estimates of $1.16, and maintains strong profitability with a 17.78% net income margin. Positive clinical trial results for Jemperli in rectal cancer and FDA approval for Utebzi highlight pipeline strength, while a pending acquisition of Nuvalent, Inc. signals strategic expansion.
GSK offers value with a P/E of 13.71 and stable cash flows, but faces risks from clinical setbacks, as seen in the terminated Alector partnership. Analyst sentiment is mixed with 31% buy ratings, reflecting cautious optimism amid competitive and regulatory pressures. The stock's outlook hinges on execution of growth initiatives and pipeline developments.
TPR stock trades at $143.67, up 6.14% today, with a bearish technical signal from moving averages but neutral oscillators. The company reported revenue of $7.01B in 2025 with net income of $183.20M, though margins compressed from prior years. Recent quarters show consistent earnings beats, and analyst sentiment remains strongly positive with a consensus price target of $184.14. Cash flow trends indicate volatility, with 2025 net cash flow negative $5.02B due to financing activities.
Outlook: Strong buy ratings and earnings momentum support upside potential, but elevated valuation ratios and technical bearishness pose near-term risks. Key opportunities include digital growth and brand strength, while risks involve margin pressure and high debt levels. Investors should weigh robust analyst confidence against fundamental headwinds for balanced positioning.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About GSK plc
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.
Read more on GSK →About Tapestry, Inc.
Coach, Kate Spade, and Stuart Weitzman are the fashion and accessory brands that comprise Tapestry. The firm's products are sold through about 1,400 company-operated stores, wholesale channels, and e-commerce in North America (67% of fiscal 2022 sales), Europe, Asia (28% of fiscal 2022 sales), and elsewhere. Coach (74% of fiscal 2022 sales) is best known for affordable luxury leather products. Kate Spade (22% of fiscal 2022 sales) is known for colorful patterns and graphics. Women's handbags and accessories produced 69% of Tapestry's sales in fiscal 2022. Stuart Weitzman, Tapestry's smallest brand, generates nearly all its revenue from women's footwear.
Read more on TPR →
